App-Quantinova.ai

Assessing change of functional connectivity using quantitative EEG after multi-domain intervention program to prevent dementia

Hae Ri Na - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dementia

N/A

CHARACTERISING SPOKEN INTERACTIONS OF HEALTHY AGEING ADULTS WITH COGNOSPEAK, A WEB-BASED COGNITIVE ASSESSMENT TOOL

Elena Brewer - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Towards a fully automatic AI framework to calculate voxel-wise atrophy in the human brain

Richard Joules - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Transposable Elements as biomarkers of Alzheimer's Disorder

Fabio Macciardi - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

A convolutional neural network algorithm for step and gait bout estimation from wristband accelerometry

Luis R Peraza - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Adjustment to test, risk and diagnostic disclosures in people with mild cognitive impairment: an observational cohort study

Stina Saunders - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Mild cognitive impairment

N/A

Assessing and disclosing test results for MCI: The Perspective of UK Old Age Psychiatrists

Stina Saunders - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dementia

N/A

PREDICTIVE FACTORS FOR CONVERSION TO DEMENTIA IN INDIVIDUALS WITH EARLY-ONSET MILD COGNITIVE IMPAIRMENT

Latha Velayudhan - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Mild cognitive impairment

N/A

The neural association between awareness of the self and of others: A brain imaging study of anosognosia and social cognition in early Alzheimer’s disease.

Jose Manuel Valera-Bermejo - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

A multimodal study on the effect of sex on Alzheimer's disease clinical and biomarker changes in adults with Down syndrome

M. Florencia Iulita - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Alzheimer's disease

N/A

Association of deep-learning-derived brain computed tomography measures with cognition and blood-based biomarkers of neurodegenerative diseases

Meera Srikrishna - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Mild cognitive impairment

N/A

Comparison of the prognostic value of cerebrospinal fluid and plasma neurofilament light in predicting longitudinal decline in white matter integrity among older adults

Elizabeth E. Moore - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dementia

N/A

Disentangling axonal loss and demyelination using multi-modal imaging: application to young onset Alzheimer’s disease

Christopher S Parker - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

Imaging neurodegeneration markers are associated with multiple pathophysiological mechanisms in the early stages of the Alzheimer’s continuum

Gemma Salvadó - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

Investigating the effects of antihypertensive medication use in AD patients using multi-modal neuroimaging

Manmohi D Dake - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Hypertension

N/A

Longitudinal FDG-PET and FTP-PET demonstrates the relationship between glucose metabolism and tau accumulation in Alzheimer’s disease atrophy-associated brain regions in cognitively normal older adults.

Harry Crook - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

Mapping associations across multiple aspects of Alzheimer disease and the role of CSF biomarkers in individuals without dementia.

Lisa Waterink - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

Microglial activation and tau propagate jointly across Braak stages

Tharick A Pascoal - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

[18F]NAV4694

Neuroimaging and neuropathological findings in older adults with COVID-19: A cognitive-neuroscience systematic review to inform the long-term impact of the virus on neurocognitive trajectories.

Riccardo Manca - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Tau and synaptic biomarkers but not amyloid-β are associated with cerebral perfusion in the Alzheimer’s disease spectrum

Khazar Ahmadi - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Mild cognitive impairment

N/A

Filters

45280 Abstracts